The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cost-effective analysis of the use of EGFR inhibitors (E) for wild-type (WT) KRAS unresectable metastatic colorectal cancer (mCRC).
Maria C. Riesco Martinez
No relevant relationships to disclose
Scott R. Berry
Consultant or Advisory Role - Amgen; Roche; Sanofi
Honoraria - Amgen; Roche; Sanofi
Yoo-Joung Ko
Consultant or Advisory Role - Amgen; Roche; Sanofi
Nicole Mittmann
Consultant or Advisory Role - Amgen; Celgene
Kelly Lien
No relevant relationships to disclose
Shazia Hassan
No relevant relationships to disclose
Angie Giotis
No relevant relationships to disclose
Kelvin K. Chan
No relevant relationships to disclose